Posted by Michael Wonder on 03 Jun 2021
U.S. FDA accepts PharmaEssentia’s BLA resubmission for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
3 June 2021 - FDA assigns a new PDUFA action date of 13 November 2021.
PharmaEssentia today announced that the United States FDA has accepted the Company’s resubmission of its biologics license application seeking approval for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera, a rare blood cancer.
